Inhibition of mGlu5 might potentially alleviate depression, Parkinson’s disease, Fragile X syndrome and chronic pain symptoms whereas positive modulation of mGlu5 may provide a new treatment for schizophrenia (Nicoletti et al., 2015). This evidence concerns the gene GRM5 and fragile X syndrome.